Podcast: Why We Need to Discuss Gene Editing and Ethics
By Jack Murtha,
Healthcare Analytics News [with CGS' Marcy Darnovsky]
| 08. 03. 2018
In 1951, Henrietta Lacks walked into Johns Hopkins Hospital complaining of vaginal bleeding. Although she died later that year, her legacy lives on. Why? Because researchers took her cells and shared them with colleagues, conducting countless studies that have fueled findings in many areas. And they did so without her permission.
Henrietta’s story is incredible on several levels: First, her cells, transformed by radium, were unique in their ability not only to survive the laboratory but to thrive. Second, she unwittingly advanced medical and scientific research. Third, she never knew of her remarkable contribution to science, making her story a case study on consent, public trust and medical ethics.
>> READ: The Complicated Ethics of Gene Editing
Now, in 2018, gene editing is no longer the stuff of science fiction. It is real, and many gene-editing therapies, such as treatments involving chimeric antigen receptor T-cells and CRISPR, could forever change medicine. They could — no, they are ushering in the age of precision medicine. Their enormous costs have also contributed to the rise of value-based care, as certain therapies earn...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...